BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
Hu Qiong-ying, Kai-zheng Wang, Yin-huan Ding, Lv-fang Zheng, Shuang-hua Liang, Zheng-ming Lei, Wen-guang Fu, Li Yan. Application of SELDI-TOF-MS Coupled With an Artificial Neural Network Model to the Diagnosis of Pancreatic CancerLaboratory Medicine 2010; 41(11): 676 doi: 10.1309/LMH6TUOMQKX6V2DN
2
Marco La Torre, Giuseppe Nigri, Annalisa lo Conte, Federica Mazzuca, Simone Maria Tierno, Adelona Salaj, Paolo Marchetti, Vincenzo Ziparo, Giovanni Ramacciato. Is a Preoperative Assessment of the Early Recurrence of Pancreatic Cancer Possible after Complete Surgical Resection?Gut and Liver 2014; 8(1): 102 doi: 10.5009/gnl.2014.8.1.102
3
Si-Biao Su, Shan-Yu Qin, Wen Chen, Wei Luo, Hai-Xing Jiang. Carbohydrate antigen 19-9 for differential diagnosis of pancreatic carcinoma and chronic pancreatitisWorld Journal of Gastroenterology 2015; 21(14): 4323-4333 doi: 10.3748/wjg.v21.i14.4323
4
Hidenori Takahashi, Hiroaki Ohigashi, Osamu Ishikawa, Hidetoshi Eguchi, Kunihito Gotoh, Terumasa Yamada, Akihiko Nakaizumi, Hiroyuki Uehara, Yasuhiko Tomita, Kinji Nishiyama, Masahiko Yano. Serum CA19–9 Alterations During Preoperative Gemcitabine-Based Chemoradiation Therapy for Resectable Invasive Ductal Carcinoma of the Pancreas as an Indicator for Therapeutic Selection and SurvivalAnnals of Surgery 2010; 251(3): 461 doi: 10.1097/SLA.0b013e3181cc90a3
5
Nicolas Santucci, Olivier Facy, Pablo Ortega-Deballon, Jean-Baptiste Lequeu, Paul Rat, Patrick Rat. CA 19–9 predicts resectability of pancreatic cancer even in jaundiced patientsPancreatology 2018; 18(6): 666 doi: 10.1016/j.pan.2018.07.001
6
Kun-Chun Chiang, Chun-Nan Yeh, Shir-Hwa Ueng, Jun-Te Hsu, Ta-Sen Yeh, Yi-Yin Jan, Tsann-Long Hwang, Miin-Fu Chen. Clinicodemographic aspect of resectable pancreatic cancer and prognostic factors for resectable cancerWorld Journal of Surgical Oncology 2012; 10(1): 77 doi: 10.1186/1477-7819-10-77
7
John P. Hoffman. Status of Neoadjuvant Therapy for Resectable Pancreatic CancerSurgical Oncology Clinics of North America 2010; 19(2): 411 doi: 10.1016/j.soc.2009.11.007
8
Renata Talar-Wojnarowska, Anita Gasiorowska, Marek Olakowski, Andrzej Lekstan, Pawel Lampe, Ewa Malecka-Panas. Clinical Value of Serum Neopterin, Tissue Polypeptide-Specific Antigen and CA19-9 Levels in Differential Diagnosis between Pancreatic Cancer and Chronic PancreatitisPancreatology 2011; 10(6): 689 doi: 10.1159/000320693
9
Erin G. Brown, Robert J. Canter, Richard J. Bold. Preoperative CA 19-9 kinetics as a prognostic variable in radiographically resectable pancreatic adenocarcinomaJournal of Surgical Oncology 2015; 111(3): 293 doi: 10.1002/jso.23812
10
Antonella De Rosa, Iain C. Cameron, Dhanwant Gomez. Indications for staging laparoscopy in pancreatic cancerHPB 2016; 18(1): 13 doi: 10.1016/j.hpb.2015.10.004
11
Young Choon Kim, Hong Joo Kim, Jung Ho Park, Dong Il Park, Yong Kyun Cho, Chong Il Sohn, Woo Kyu Jeon, Byung Ik Kim, Jun Ho Shin. Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma?Journal of Gastroenterology and Hepatology 2009; 24(12): 1869 doi: 10.1111/j.1440-1746.2009.05935.x
12
Holger Husi, Richard J. E. Skipworth, Andrew Cronshaw, Nathan A. Stephens, Henning Wackerhage, Carolyn Greig, Kenneth C. H. Fearon, James A. Ross. Programmed cell death 6 interacting protein (PDCD6IP) and Rabenosyn-5 (ZFYVE20) are potential urinary biomarkers for upper gastrointestinal cancerPROTEOMICS - Clinical Applications 2015; 9(5-6): 586 doi: 10.1002/prca.201400111
13
Mina Waraya, Keishi Yamashita, Hiroyuki Katagiri, Kenichiro Ishii, Yoshihito Takahashi, Kazunori Furuta, Masahiko Watanabe. Preoperative Serum CA19-9 and Dissected Peripancreatic Tissue Margin as Determiners of Long-Term Survival in Pancreatic CancerAnnals of Surgical Oncology 2009; 16(5): 1231 doi: 10.1245/s10434-009-0415-7
14
Mitsuro Kanda, Tsutomu Fujii, Hideki Takami, Masaya Suenaga, Yoshikuni Inokawa, Suguru Yamada, Goro Nakayama, Hiroyuki Sugimoto, Masahiko Koike, Shuji Nomoto, Yasuhiro Kodera. The combination of the serum carbohydrate antigen 19-9 and carcinoembryonic antigen is a simple and accurate predictor of mortality in pancreatic cancer patientsSurgery Today 2014; 44(9): 1692 doi: 10.1007/s00595-013-0752-9
15
O. Turrini, C. M. Schmidt, J. Moreno, P. Parikh, J. M. Matos, M. G. House, N. J. Zyromski, A. Nakeeb, H. A. Pitt, K. D. Lillemoe. Very High Serum CA 19-9 Levels: A Contraindication to Pancreaticoduodenectomy?Journal of Gastrointestinal Surgery 2009; 13(10): 1791 doi: 10.1007/s11605-009-0916-5
16
Salvatore Scarà, Patrizia Bottoni, Roberto Scatena. Advances in Cancer BiomarkersAdvances in Experimental Medicine and Biology 2015; 867: 247 doi: 10.1007/978-94-017-7215-0_15
17
Hala O. El-Mesallamy, Nadia M. Hamdy, Ashraf S. Zaghloul, Alaliaa M. Sallam. Clinical Value of Circulating Lipocalins and Insulin-Like Growth Factor Axis in Pancreatic Cancer DiagnosisPancreas 2013; 42(1): 149 doi: 10.1097/MPA.0b013e3182550d9d
18
Kimberly M. Brown. Multidisciplinary Approach to Tumors of the Pancreas and Biliary TreeSurgical Clinics of North America 2009; 89(1): 115 doi: 10.1016/j.suc.2008.09.022
19
Umashankar K. Ballehaninna, Ronald S. Chamberlain. Serum CA 19-9 as a Biomarker for Pancreatic Cancer—A Comprehensive ReviewIndian Journal of Surgical Oncology 2011; 2(2): 88 doi: 10.1007/s13193-011-0042-1
20
Su Kah Goh, Grace Gold, Christopher Christophi, Vijayaragavan Muralidharan. Serum carbohydrate antigen 19-9 in pancreatic adenocarcinoma: a mini review for surgeonsANZ Journal of Surgery 2017; 87(12): 987 doi: 10.1111/ans.14131
21
Kavya Krishna, Tanios Bekaii-Saab. Biomarkers in Cancer2014; : 1 doi: 10.1007/978-94-007-7744-6_17-1
22
Kohei Nishio, Kenjiro Kimura, Ryosuke Amano, Sadaaki Yamazoe, Go Ohrira, Bunzo Nakata, Kosei Hirakawa, Masaichi Ohira. Preoperative predictors for early recurrence of resectable pancreatic cancerWorld Journal of Surgical Oncology 2017; 15(1) doi: 10.1186/s12957-016-1078-z
23
Zhenhua Ma, Qingyong Ma, Zheng Wang. An evaluation of the diagnostic value of CA19-9 and CEA levels in patients with pancreatic cancerJournal of Nanjing Medical University 2009; 23(3): 199 doi: 10.1016/S1007-4376(09)60055-1
24
Ludmila Katherine Martin, Lai Wei, Elizabeth Trolli, Tanios Bekaii-Saab. Elevated baseline CA19-9 levels correlate with adverse prognosis in patients with early- or advanced-stage pancreas cancerMedical Oncology 2012; 29(5): 3101 doi: 10.1007/s12032-012-0278-9
25
Jason C. Maggi, Melissa E. Hogg, Amer H. Zureikat, Herbert J. Zeh. Update on the Management of Pancreatic Cancer: Determinants for Surgery and Widening the Therapeutic Window of Surgical ResectionCurrent Surgery Reports 2016; 4(7) doi: 10.1007/s40137-016-0146-1
26
Gian Carlo Mattiucci, Alessio G. Morganti, Francesco Cellini, Milly Buwenge, Riccardo Casadei, Andrea Farioli, Sergio Alfieri, Alessandra Arcelli, Federica Bertini, Felipe A. Calvo, Silvia Cammelli, Lorenzo Fuccio, Lucia Giaccherini, Alessandra Guido, Joseph M. Herman, Gabriella Macchia, Bert W. Maidment, Robert C. Miller, Francesco Minni, William F. Regine, Michele Reni, Stefano Partelli, Massimo Falconi, Vincenzo Valentini. Prognostic Impact of Presurgical CA19-9 Level in Pancreatic Adenocarcinoma: A Pooled AnalysisTranslational Oncology 2019; 12(1): 1 doi: 10.1016/j.tranon.2018.08.017
27
Masaki Kuwatani, Hiroshi Kawakami, Yoshimasa Kubota, Kazumichi Kawakubo, Yoichi M. Ito, Shinji Togo, Takaaki Ikeda, Ken Kusama, Yuka Kobayashi, Teizo Murata, Naoya Sakamoto. Verification of the effectiveness of fucosylated haptoglobin as a pancreatic cancer marker in clinical diagnosisPancreatology 2019; 19(4): 569 doi: 10.1016/j.pan.2019.04.007
28
Lisheng Qian, Qiaobin Li, Kwaku Baryeh, Wanwei Qiu, Kun Li, Jing Zhang, Qingcai Yu, Dongqin Xu, Wenju Liu, Randall E. Brand, Xueji Zhang, Wei Chen, Guodong Liu. Biosensors for early diagnosis of pancreatic cancer: a reviewTranslational Research 2019; 213: 67 doi: 10.1016/j.trsl.2019.08.002
29
Jesse Hinton, Richard Callan, Charlie Bodine, Wayne Glasgow, Steve Brower, Shi-Wen Jiang, Jinping Li. Potential epigenetic biomarkers for the diagnosis and prognosis of pancreatic ductal adenocarcinomasExpert Review of Molecular Diagnostics 2013; 13(5): 431 doi: 10.1586/erm.13.38
30
Kavya Krishna, Tanios Bekaii-Saab. Biomarkers in CancerBiomarkers in Disease: Methods, Discoveries and Applications 2015; : 179 doi: 10.1007/978-94-007-7681-4_17
31
Si Shi, Xianjun Yu. Selecting chemotherapy for pancreatic cancer: Far away or so close?Seminars in Oncology 2019; 46(1): 39 doi: 10.1053/j.seminoncol.2018.12.004
32
Naru Kondo, Yoshiaki Murakami, Kenichiro Uemura, Yasuo Hayashidani, Takeshi Sudo, Yasushi Hashimoto, Akira Nakashima, Ryutaro Sakabe, Norifumi Shigemoto, Yasushi Kato, Hiroki Ohge, Taijiro Sueda. Prognostic Impact of Perioperative Serum CA 19-9 Levels in Patients with Resectable Pancreatic CancerAnnals of Surgical Oncology 2010; 17(9): 2321 doi: 10.1245/s10434-010-1033-0
33
Maria Diab, Philip A. Philip. Current and Emerging Therapies in Pancreatic Cancer2018; : 119 doi: 10.1007/978-3-319-58256-6_6
34
Giovanni Guarneri, Giulia Gasparini, Stefano Crippa, Valentina Andreasi, Massimo Falconi. Diagnostic strategy with a solid pancreatic massLa Presse Médicale 2019; 48(3): e125 doi: 10.1016/j.lpm.2019.02.026
35
Ray Greek, Mark J Rice. Animal models and conserved processesTheoretical Biology and Medical Modelling 2012; 9(1) doi: 10.1186/1742-4682-9-40
36
Roopali Roy, Christine M. Coticchia, Jiang Yang, Marsha A. Moses. Biomarkers2010; : 355 doi: 10.1002/9780470918562.ch14